Exicure, Inc. Common Stock
XCURExicure, Inc. (XCUR) is a biotechnology company focused on developing innovative nucleic acid therapeutics using its proprietary spherical nucleic acid (SNA) technology. The company aims to address challenging genetic and inflammatory diseases with its platform, which facilitates targeted gene regulation and modulation. Based in Chicago, Exicure leverages its scientific expertise to advance therapies in areas such as oncology, dermatology, and immunology.
Company News
Exicure, Inc. (Nasdaq: XCUR) received a notification from Nasdaq on May 28, 2026 for non-compliance with listing rules due to delayed filing of its Q1 2026 Form 10-Q. The delay was attributed to changes in financial reporting personnel and procedures. The company filed the report on May 29, 2026 and believes it has regained compliance.
Exicure, Inc. announced a co-development agreement with Korea-based Adbiotech to explore combination therapies using Burixafor (GPC-100) across multiple therapeutic areas including sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech will conduct in vivo studies while Exicure provides Burixafor and leads clinical strategy. The...
Exicure announced publication of Phase 2 data for burixafor, a CXCR4 inhibitor, demonstrating rapid stem cell mobilization in multiple myeloma and lymphoma patients. The study showed 92% of participants met primary endpoints with same-day cell collection capability, significantly faster than currently approved alternatives. The drug was well-tole...
Exicure, Inc. announced it will present positive Phase 2 trial data for burixafor at the 2026 Tandem Meetings in Salt Lake City. The trial evaluated burixafor's ability to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous transplantation, with 89.7% of patients meeting the primary endpoint and demonstratin...
Exicure reported a net loss of $2.4 million in Q3 2025, with reduced cash reserves and insufficient funding to continue operations. The company is exploring strategic alternatives and seeking additional financing.
